<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121860</url>
  </required_header>
  <id_info>
    <org_study_id>IDN-6556-08</org_study_id>
    <nct_id>NCT02121860</nct_id>
  </id_info>
  <brief_title>PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers</brief_title>
  <official_title>An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conatus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conatus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, parallel-group study to compare the pharmacokinetics and
      pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with
      mild, moderate, and severe hepatic impairment (defined as Child-Pugh A, B, and C,
      respectively) and matched healthy volunteers with normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>48 Hours</time_frame>
    <description>Area under the plasma concentration curve (AUC) to 12 hours post-dose (AUC0-12); AUC to the last observed plasma concentration (AUClast);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 Hours</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of cCK18/M30</measure>
    <time_frame>predose, 0.5, 1,2,3,4,5,8,12,24, and 48 hours post dose</time_frame>
    <description>Caspase-cleaved cytokeratin levels (cCK18M30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Caspase 3/7 RLU</measure>
    <time_frame>predose, 0.5, 1,2,3,4,5,8,12,24, and 48 hours post dose</time_frame>
    <description>Concentration of Caspase 3/7 Relative Light Units</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Liver Diseases</condition>
  <condition>Digestive System Diseases</condition>
  <arm_group>
    <arm_group_label>Chil-Pugh Class A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chil-Pugh Class B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chil-Pugh Class C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDN-6556</intervention_name>
    <arm_group_label>Chil-Pugh Class A</arm_group_label>
    <arm_group_label>Chil-Pugh Class B</arm_group_label>
    <arm_group_label>Chil-Pugh Class C</arm_group_label>
    <arm_group_label>Normal Hepatic Function</arm_group_label>
    <other_name>emricasan</other_name>
    <other_name>PF-03491390</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All Subjects:

          -  Male or female subjects 18 years of age or older, able to provide written informed
             consent, understand and comply with all scheduled visits, and other requirements of
             the study

          -  Body mass index (BMI) 18.0 - 40.0 kg/m2 and body weight &gt;45 kg

          -  Willingness to utilize two reliable forms of contraception (for both males and females
             of childbearing potential) from Screening to one month after the last dose of study
             drug

        Matched Healthy Volunteers:

          -  Medically healthy as determined by the Investigator

          -  Supine blood pressure ≤145/90 mmHg

          -  No significant uncontrolled systemic or major illness that, in the opinion of the
             Investigator, would preclude the subject from participating in and completing the
             study

          -  Demographically comparable to subjects with hepatic impairment as follows:

               1. Mean body weight within ±15 kg

               2. Mean age within ±10 years

               3. Similar gender ratio

        Subjects with Hepatic Impairment:

          -  Evidence of hepatic disease

               1. Score ≥ 2 on one of the Child-Pugh parameters, or

               2. Histological or imaging diagnosis of cirrhosis, or

               3. Presence of esophageal varices, or

               4. Abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST), or
                  alkaline phosphatase (ALP) levels

          -  Meet one of the following criteria for Child-Pugh classification for hepatic
             impairment during Screening

               1. Mild hepatic impairment: Class A (Child-Pugh Scores 5-6 points)

               2. Moderate hepatic impairment: Class B (Child-Pugh Scores 7-9 points)

               3. Severe hepatic impairment: Class C (Child Pugh Scores 10-15 points)

          -  Supine blood pressure ≤160/100 mmHg

        Exclusion Criteria:

        All Subjects:

          -  Known infection with human immunodeficiency virus (HIV) upon serological testing

          -  Evidence of clinically significant uncontrolled hematological, endocrine, pulmonary,
             gastrointestinal, cardiovascular, renal, psychiatric, neurologic, or allergic disease
             (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
             at time of dosing)

          -  Disorders or surgery of the gastrointestinal tract which may interfere with drug
             absorption or may otherwise influence the pharmacokinetics of the investigational
             medicinal product (e.g., inflammatory bowel disease, resections of the small or large
             intestine, etc.)

          -  History of febrile illness within 5 days prior to dosing Note: Subjects can be
             rescreened once afebrile and more than 5 days have elapsed since the febrile illness.

          -  Known ongoing drug abuse within one month prior to dosing, or evidence of such abuse
             as indicated by the laboratory assays conducted during Screening and/or at Day -1

          -  Subjects with active or history of malignancies other than curatively treated skin
             cancer (basal cell or squamous cell carcinomas)

          -  Dosing in another clinical trial within 30 days prior to the study drug administration

          -  If female: known pregnancy, positive urine or serum pregnancy test, or
             lactating/breastfeeding

        Matched Healthy Volunteers:

          -  Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or
             C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease,
             elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that is
             considered clinically significant by the Investigator, etc.)

          -  Screening creatinine clearance &lt;80 mL/min using the Cockcroft-Gault equation

          -  History or presence of clinically concerning cardiac arrhythmias, or prolongation of
             Screening (pre-treatment) QT or QTc interval of &gt;450 milliseconds (msec)

          -  History of regular alcohol consumption exceeding 28 drinks/week (1 drink = 150 mL of
             wine or 360 mL of beer or 45 mL of spirits) within 6 months of Screening

        Subjects with Hepatic Impairment:

          -  Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly
             varying or worsening of clinical and/or laboratory signs of hepatic impairment during
             Screening period and up to Day -1 (e.g., advanced ascites, infection of ascites,
             fever, active gastrointestinal bleeding)

          -  History of liver transplant, or have a transjugular intrahepatic portosystemic shunt,
             and/or have undergone portacaval shunting

          -  History or presence of clinically concerning cardiac arrhythmias, or prolongation of
             Screening (pre-treatment) QT or QTc interval of &gt;480 milliseconds (msec)

          -  Screening creatinine clearance &lt;50 mL/min using the Cockcroft-Gault equation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Hagerty, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Conatus Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2014</study_first_posted>
  <results_first_submitted>September 25, 2015</results_first_submitted>
  <results_first_submitted_qc>January 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2016</results_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open-label, multicenter, parallel-group study to compare the PK and PD of IDN 6556 following a single 50 mg oral dose of IDN-6556 in subjects with mild, moderate, and severe hepatic impairment (defined as Child-Pugh A, B, and C, respectively) and matched healthy volunteers (subjects with normal hepatic function).</recruitment_details>
      <pre_assignment_details>A total of 37 subjects were dosed. One subject was dosed twice at two different centers, so the analyzed sample size was 36 subjects: 12 subjects with mild, and 8 subjects each with moderate and severe hepatic impairment, and with normal hepatic function.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Hepatic Function</title>
          <description>Medically healthy as determined by the investigator</description>
        </group>
        <group group_id="P2">
          <title>Child-Pugh Class A</title>
          <description>Mild hepatic impairment</description>
        </group>
        <group group_id="P3">
          <title>Child-Pugh Class B</title>
          <description>Moderate hepatic impairment</description>
        </group>
        <group group_id="P4">
          <title>Child-Pugh Class C</title>
          <description>Severe hepatic impairment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects with normal hepatic function were matched for weight, age, and gender to subjects with severe hepatic impairment. The subjects mean age was 56 years. In all subject groups, more male than female subjects, with no female subjects in the moderate hepatic impairment group. The majority of subjects were White (92%).</population>
      <group_list>
        <group group_id="B1">
          <title>Child-Pugh Class A</title>
          <description>Mild Hepatic Impairment</description>
        </group>
        <group group_id="B2">
          <title>Child-Pugh Class B</title>
          <description>Moderate Hepatic Impairment</description>
        </group>
        <group group_id="B3">
          <title>Child-Pugh Class C</title>
          <description>Severe Hepatic Impairment</description>
        </group>
        <group group_id="B4">
          <title>Normal Hepatic Function</title>
          <description>Medically healthy as determined by the investigator</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="8.8"/>
                    <measurement group_id="B2" value="54.1" spread="7.1"/>
                    <measurement group_id="B3" value="57.4" spread="4.8"/>
                    <measurement group_id="B4" value="57.6" spread="4.9"/>
                    <measurement group_id="B5" value="55.9" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>Area under the plasma concentration curve (AUC) to 12 hours post-dose (AUC0-12); AUC to the last observed plasma concentration (AUClast);</description>
        <time_frame>48 Hours</time_frame>
        <population>The analyzed sample size was 36 subjects: 12 subjects with mild, and 8 subjects each with moderate and severe hepatic impairment, and with normal hepatic function.</population>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Medically healthy as determined by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Child-Pugh Class A</title>
            <description>Mild Hepatic Impairment</description>
          </group>
          <group group_id="O3">
            <title>Child-Pugh Class B</title>
            <description>Moderate Hepatic Impairment</description>
          </group>
          <group group_id="O4">
            <title>Child-Pugh Class C</title>
            <description>Severe Hepatic Impairment</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>Area under the plasma concentration curve (AUC) to 12 hours post-dose (AUC0-12); AUC to the last observed plasma concentration (AUClast);</description>
          <population>The analyzed sample size was 36 subjects: 12 subjects with mild, and 8 subjects each with moderate and severe hepatic impairment, and with normal hepatic function.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-12 (h*ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.5" spread="51.1"/>
                    <measurement group_id="O2" value="114.6" spread="36.0"/>
                    <measurement group_id="O3" value="423.7" spread="126.1"/>
                    <measurement group_id="O4" value="1042" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUClast (h*ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.6" spread="47.1"/>
                    <measurement group_id="O2" value="118.2" spread="33.0"/>
                    <measurement group_id="O3" value="435.7" spread="121.7"/>
                    <measurement group_id="O4" value="1083" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of cCK18/M30</title>
        <description>Caspase-cleaved cytokeratin levels (cCK18M30)</description>
        <time_frame>predose, 0.5, 1,2,3,4,5,8,12,24, and 48 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Medically healthy as determined by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Child-Pugh Class A</title>
            <description>Mild Hepatic Impairment</description>
          </group>
          <group group_id="O3">
            <title>Child-Pugh Class B</title>
            <description>Moderate Hepatic Impairment</description>
          </group>
          <group group_id="O4">
            <title>Child-Pugh Class C</title>
            <description>Severe Hepatic Impairment</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of cCK18/M30</title>
          <description>Caspase-cleaved cytokeratin levels (cCK18M30)</description>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.5" lower_limit="123.0" upper_limit="236.0"/>
                    <measurement group_id="O2" value="147.5" lower_limit="110.5" upper_limit="293.5"/>
                    <measurement group_id="O3" value="348.0" lower_limit="200.0" upper_limit="601.5"/>
                    <measurement group_id="O4" value="517.0" lower_limit="340.5" upper_limit="552.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.0" lower_limit="141.5" upper_limit="174.0"/>
                    <measurement group_id="O2" value="153.0" lower_limit="124.0" upper_limit="322.5"/>
                    <measurement group_id="O3" value="433.5" lower_limit="188.0" upper_limit="578.5"/>
                    <measurement group_id="O4" value="506.5" lower_limit="348.5" upper_limit="551.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.5" lower_limit="139.0" upper_limit="189.0"/>
                    <measurement group_id="O2" value="170.5" lower_limit="122.0" upper_limit="276.5"/>
                    <measurement group_id="O3" value="380.5" lower_limit="224.5" upper_limit="560.0"/>
                    <measurement group_id="O4" value="471.0" lower_limit="344.0" upper_limit="499.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.0" lower_limit="130.5" upper_limit="183.0"/>
                    <measurement group_id="O2" value="153.0" lower_limit="109.0" upper_limit="247.0"/>
                    <measurement group_id="O3" value="376.5" lower_limit="205.0" upper_limit="471.0"/>
                    <measurement group_id="O4" value="446.5" lower_limit="345.0" upper_limit="531.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.5" lower_limit="146.5" upper_limit="212.5"/>
                    <measurement group_id="O2" value="167.0" lower_limit="108.5" upper_limit="250.5"/>
                    <measurement group_id="O3" value="322.5" lower_limit="176.0" upper_limit="422.0"/>
                    <measurement group_id="O4" value="388.0" lower_limit="307.0" upper_limit="493.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.5" lower_limit="144.0" upper_limit="190.0"/>
                    <measurement group_id="O2" value="156.5" lower_limit="110.5" upper_limit="249.0"/>
                    <measurement group_id="O3" value="295.5" lower_limit="196.0" upper_limit="361.0"/>
                    <measurement group_id="O4" value="362.0" lower_limit="287.0" upper_limit="437.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.5" lower_limit="138.5" upper_limit="184.5"/>
                    <measurement group_id="O2" value="161.5" lower_limit="102.0" upper_limit="187.0"/>
                    <measurement group_id="O3" value="229.0" lower_limit="164.5" upper_limit="350.0"/>
                    <measurement group_id="O4" value="358.0" lower_limit="243.5" upper_limit="415.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.0" lower_limit="127.5" upper_limit="205.0"/>
                    <measurement group_id="O2" value="126.0" lower_limit="104.0" upper_limit="172.0"/>
                    <measurement group_id="O3" value="190.5" lower_limit="110.5" upper_limit="307.0"/>
                    <measurement group_id="O4" value="274.5" lower_limit="208.5" upper_limit="343.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.5" lower_limit="135.0" upper_limit="219.5"/>
                    <measurement group_id="O2" value="104.5" lower_limit="84.5" upper_limit="164.5"/>
                    <measurement group_id="O3" value="137.5" lower_limit="110.5" upper_limit="249.5"/>
                    <measurement group_id="O4" value="287.5" lower_limit="164.0" upper_limit="356.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.5" lower_limit="134.0" upper_limit="191.5"/>
                    <measurement group_id="O2" value="151.0" lower_limit="104.0" upper_limit="213.5"/>
                    <measurement group_id="O3" value="298.0" lower_limit="183.0" upper_limit="339.5"/>
                    <measurement group_id="O4" value="423.0" lower_limit="331.5" upper_limit="488.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.0" lower_limit="141.0" upper_limit="269.5"/>
                    <measurement group_id="O2" value="193.0" lower_limit="121.5" upper_limit="283.0"/>
                    <measurement group_id="O3" value="353.5" lower_limit="244.0" upper_limit="555.5"/>
                    <measurement group_id="O4" value="508.5" lower_limit="381.0" upper_limit="581.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Caspase 3/7 RLU</title>
        <description>Concentration of Caspase 3/7 Relative Light Units</description>
        <time_frame>predose, 0.5, 1,2,3,4,5,8,12,24, and 48 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Medically healthy as determined by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Child-Pugh Class A</title>
            <description>Mild Hepatic Impairment</description>
          </group>
          <group group_id="O3">
            <title>Child-Pugh Class B</title>
            <description>Moderate Hepatic Impairment</description>
          </group>
          <group group_id="O4">
            <title>Child-Pugh Class C</title>
            <description>Severe Hepatic Impairment</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Caspase 3/7 RLU</title>
          <description>Concentration of Caspase 3/7 Relative Light Units</description>
          <units>RLU</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="963.5" lower_limit="753.5" upper_limit="1554.0"/>
                    <measurement group_id="O2" value="1158.5" lower_limit="862.5" upper_limit="1547.5"/>
                    <measurement group_id="O3" value="2006.0" lower_limit="1537.0" upper_limit="2394.5"/>
                    <measurement group_id="O4" value="1662.5" lower_limit="1256.5" upper_limit="2194.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>.5 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="900.5" lower_limit="835.5" upper_limit="1398.5"/>
                    <measurement group_id="O2" value="1130.5" lower_limit="852.5" upper_limit="1386.0"/>
                    <measurement group_id="O3" value="2027.0" lower_limit="1391.5" upper_limit="2276.0"/>
                    <measurement group_id="O4" value="1933.5" lower_limit="1557.0" upper_limit="2915.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="850.5" lower_limit="766.5" upper_limit="1078.5"/>
                    <measurement group_id="O2" value="1260.5" lower_limit="814.5" upper_limit="1297.5"/>
                    <measurement group_id="O3" value="1482.0" lower_limit="1169.0" upper_limit="1821.0"/>
                    <measurement group_id="O4" value="1392.0" lower_limit="1096.0" upper_limit="1814.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820.0" lower_limit="772.0" upper_limit="1111.0"/>
                    <measurement group_id="O2" value="1048.0" lower_limit="873.5" upper_limit="1311.5"/>
                    <measurement group_id="O3" value="1121.0" lower_limit="961.5" upper_limit="1270.0"/>
                    <measurement group_id="O4" value="1090.0" lower_limit="674.5" upper_limit="1482.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="872.0" lower_limit="746.5" upper_limit="1084.5"/>
                    <measurement group_id="O2" value="1027.0" lower_limit="888.5" upper_limit="1170.5"/>
                    <measurement group_id="O3" value="906.5" lower_limit="858.0" upper_limit="1238.5"/>
                    <measurement group_id="O4" value="796.0" lower_limit="618.0" upper_limit="958.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="848.5" lower_limit="789.0" upper_limit="1085.0"/>
                    <measurement group_id="O2" value="921.0" lower_limit="795.5" upper_limit="1097.0"/>
                    <measurement group_id="O3" value="984.5" lower_limit="887.0" upper_limit="1170.0"/>
                    <measurement group_id="O4" value="806.5" lower_limit="571.0" upper_limit="949.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="836.5" lower_limit="792.5" upper_limit="1142.0"/>
                    <measurement group_id="O2" value="976.0" lower_limit="823.0" upper_limit="1178.0"/>
                    <measurement group_id="O3" value="903.5" lower_limit="856.5" upper_limit="1312.5"/>
                    <measurement group_id="O4" value="776.0" lower_limit="694.5" upper_limit="935.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="916.0" lower_limit="797.5" upper_limit="1263.0"/>
                    <measurement group_id="O2" value="1088.5" lower_limit="929.0" upper_limit="1216.5"/>
                    <measurement group_id="O3" value="1084.5" lower_limit="921.5" upper_limit="1410.0"/>
                    <measurement group_id="O4" value="893.5" lower_limit="750.5" upper_limit="1275.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876.5" lower_limit="686.5" upper_limit="1002.0"/>
                    <measurement group_id="O2" value="1039.0" lower_limit="793.0" upper_limit="1170.5"/>
                    <measurement group_id="O3" value="1230.5" lower_limit="992.0" upper_limit="1516.5"/>
                    <measurement group_id="O4" value="1187.0" lower_limit="924.5" upper_limit="1478.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="842.0" lower_limit="723.5" upper_limit="1060.0"/>
                    <measurement group_id="O2" value="1227.5" lower_limit="949.5" upper_limit="1344.5"/>
                    <measurement group_id="O3" value="1798.5" lower_limit="1308.5" upper_limit="2128.5"/>
                    <measurement group_id="O4" value="1276.0" lower_limit="1027.0" upper_limit="2907.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="991.5" lower_limit="719.5" upper_limit="1149.5"/>
                    <measurement group_id="O2" value="1291.0" lower_limit="877.5" upper_limit="1534.0"/>
                    <measurement group_id="O3" value="1754.0" lower_limit="1440.5" upper_limit="2243.5"/>
                    <measurement group_id="O4" value="1457.5" lower_limit="1097.0" upper_limit="2685.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum concentration (Cmax)</description>
        <time_frame>48 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Hepatic Function</title>
            <description>Medically healthy as determined by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Child-Pugh Class A</title>
            <description>Mild Hepatic Impairment</description>
          </group>
          <group group_id="O3">
            <title>Child-Pugh Class B</title>
            <description>Moderate Hepatic Impairment</description>
          </group>
          <group group_id="O4">
            <title>Child-Pugh Class C</title>
            <description>Severe Hepatic Impairment</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum concentration (Cmax)</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.01" spread="70.4"/>
                    <measurement group_id="O2" value="37.45" spread="64.9"/>
                    <measurement group_id="O3" value="127.2" spread="146.6"/>
                    <measurement group_id="O4" value="322.2" spread="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IDN-6556</title>
          <description>Single 50 mg oral dose of IDN-6556</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pulpitis Dental</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean L. Chan, MD</name_or_title>
      <organization>Conatus Pharmaceuticals</organization>
      <phone>(858) 376-2632</phone>
      <email>jchan@conatuspharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

